Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: hartung hp. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernández O, Seeldrayers P, Sørensen P, Margrie S, Rovaris M, Comi G, Filippi M; Early Treatment of Multiple Sclerosis Study Group. Barkhof F, et al. Among authors: hartung hp. Ann Neurol. 2003 Jun;53(6):718-24. doi: 10.1002/ana.10551. Ann Neurol. 2003. PMID: 12783417 Clinical Trial.
Statins as potential therapeutic agents in multiple sclerosis.
Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS. Stüve O, et al. Among authors: hartung hp. Curr Neurol Neurosci Rep. 2004 May;4(3):237-44. doi: 10.1007/s11910-004-0044-2. Curr Neurol Neurosci Rep. 2004. PMID: 15102350 Review.
European validation of a standardized clinical description of multiple sclerosis.
Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C; Evaluation of the EDMUS system (EVALUED) Study Group. Amato MP, et al. Among authors: hartung hp. J Neurol. 2004 Dec;251(12):1472-80. doi: 10.1007/s00415-004-0567-0. J Neurol. 2004. PMID: 15645346
Evidence for use of glatiramer acetate in multiple sclerosis.
Comi G, Hartung HP, Martinelli Boneschi F. Comi G, et al. Among authors: hartung hp. Lancet Neurol. 2005 Feb;4(2):75-6; discussion 76-7. doi: 10.1016/S1474-4422(05)00975-0. Lancet Neurol. 2005. PMID: 15664539 No abstract available.
10 years of interferon beta-1b (Beta feron therapy.
Kappos L, Hartung HP. Kappos L, et al. Among authors: hartung hp. J Neurol. 2005 Sep;252 Suppl 3:iii1-iii2. doi: 10.1007/s00415-005-2009-z. J Neurol. 2005. PMID: 16170493 Review. No abstract available.
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: hartung hp. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.
1,136 results